EANS-News: Epigenomics AG / Epigenomics AG Announces Changes to Management Team

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Management Changes/Company

Berlin (euro adhoc) - Press release

Epigenomics AG Announces Changes to Management Team

Berlin, Germany, and Seattle, WA, U.S.A., September 25, 2012 -
Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American
cancer molecular diagnostics company, today announced that Dr. Thomas
Taapken, currently Chief Financial Officer at Epigenomics, has been
appointed by the Board of Directors to serve as acting Chief
Executive Officer in addition to his responsibilities as CFO,
effective 1 October 2012. He will replace Geert Nygaard who agreed
with the Supervisory Board of the Company that he will leave the
Executive Management of the company effective September 30, 2012.

The Supervisory Board concomitantly also widened the responsibilities
of Dr. Uwe Staub, currently Senior Vice President for Research &
Development, promoted him to COO and granted him "Prokura" (power of
attorney). His current duties will be expanded by the responsibility
for Medical and Regulatory Affairs and Customer Support.

"We are very pleased to be announcing the appointment of Thomas
Taapken to the position of acting CEO in addition to his role as CFO
and have full confidence that Thomas will be able to guide the
Company through its most critical near-term milestones including the
submission of the final Premarket Approval (PMA) module for Epi
proColon® and subsequent U.S. FDA approval but will also be pivotal
in helping secure the financial resources necessary to fund the
operations beyond its current cash reach," said Heino von
Prondzynski, Epigenomics' Chairman of the Board. "Thomas has proven
to be a significant leader with extensive industry insight and
experience including a background in corporate development, venture
capital, and management leadership. Furthermore, he has a keen
understanding of a company's need to drive shareholder value and the
Board of Directors is very pleased that he has agreed to accept this
additional challenge."

"We are also extremely pleased that Dr. Uwe Staub has accepted the
newly created function of COO accumulating Medical and Regulatory
Affairs and Customer Service to his already existing Leadership in
R&D and Operations. He and his actual team have so far reached all
promised milestones. Due to their significant contributions the
company is fully on track to complete the FDA submission later this
year and to reach its ultimate goal of introducing Epi proColon® as
the first approved blood-based test for the early detection of
colorectal cancer into the U.S. market, milestones extremely
important for the near and mid-term future of the company. Reducing
the Board to one person is also a significant step in reducing the
burn-rate, a task which is on the top of the Management and Board
agenda."

"On behalf of the Board of Directors, I would like to thank Geert
Nygaard for his dedication to the Company for the past five and half
years. Under his leadership, Epigenomics transformed from a research
based organization to a commercially focused company with two
products on the market. We wish him well in his future endeavors."

"I am honored to be appointed by the Supervisory Board as the Company's acting
CEO and am truly excited by the prospect of leading Epigenomics together with my
senior management colleagues during this time of significant changes", said
Thomas Taapken. "As we await the results of the head-to-head comparative study
of Epi proColon® to fecal immunochemical testing (FIT) which are expected in the
fourth quarter we are appropriately conducting pre-marketing activities to build
additional awareness of the test and are speaking with private payors and key
leaders in colorectal cancer. We remain committed to filing the last module of
our PMA soon after the FIT comparison study is completed and I look forward to
keeping you apprised of our clinical and regulatory activities. At the same
time, we will be making the necessary decisions to secure additional financing
in order to extend the current cash reach of the company beyond its most
critical milestones"

- Ends -

Contact Epigenomics AG

Antje Zeise

Manager IR | PR
Epigenomics AG
Tel +49 (0) 30 24345 368
ir@epigenomics.com
www.epigenomics.com

About Epigenomics Epigenomics (www.epigenomics.com) is a molecular
diagnostics company developing and commercializing a pipeline of
proprietary products for cancer. The Company's products enable
doctors to diagnose cancer earlier and more accurately, leading to
improved outcomes for patients. Epigenomics' lead product, Epi
proColon®, is a blood-based test for the early detection of
colorectal cancer, which is currently marketed in Europe and is in
development for the U.S.A. The Company's technology and products have
been validated through multiple partnerships with leading global
diagnostic companies including Abbott, QIAGEN, Sysmex, and Quest
Diagnostics. Epigenomics is an international company with operations
in Europe and the U.S.A.

Epigenomics legal disclaimer This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale by
Epigenomics in the United States or Canada. The analytical and
clinical performance characteristics of any Epigenomics product based
on this technology which may be sold at some future time in the U.S.
have not been established.

Further inquiry note:
Antje Zeise | CIRO
Manager IR/PR
Epigenomics AG
Tel: +49 30 24345 386

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: Epigenomics AG
Kleine Präsidentenstraße 1
D-10178 Berlin
phone: +49 30 24345-0
FAX: +49 30 24345-555
mail: ir@epigenomics.com
WWW: http://www.epigenomics.com
sector: Biotechnology
ISIN: DE000A1K0516
indexes: Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
regulated dealing/prime standard: Frankfurt
language: English